http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014108478-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0623 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0793 |
| filingDate | 2012-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014108478-A |
| titleOfInvention | CELL COMPOSITION, PHARMACEUTICAL COMPOSITION, SET AND METHOD FOR TREATING DEGENERATIVE DISEASES OF THE EGG NET (OPTIONS) |
| abstract | 1. The use of a mesenchymal stem cell (MSC) or a cell population containing a hematopoietic stem cell (HSC), a progenitor cell and a mesenchymal stem cell (MSC), characterized by activation of the Wnt / β-catenin signaling pathway in the treatment of degenerative disease of the retina through direct implantation of these cells into the eye of a patient in need of treatment. 2. The use of claim 1, wherein the cells are cells treated with a Wnt / β-catenin signaling pathway activator or an inhibitor of a Wnt / β-catenin signaling pathway inhibitor and / or are cells overexpressing a Wnt / β-catenin signaling pathway activator. The use of claim 2, wherein the Wnt / β-catenin signaling pathway activator is a Wnt / β-catenin signaling pathway activator selected from the group consisting of Wnt isoform, β-catenin, R-spondin, 2- (4-acetylphenylazo) - 2- (3,3-dimethyl-3,4-dihydro-2H-isoquinolin-1-ylidene) -acetamide (IQ1), (2S) -2- [2- (indan-5-yloxy) -9- (1 , 1′-biphenyl-4) methyl) -9H-purin-6-ylamino] -3-phenyl-propan-1-ol (QS11), deoxycholic acid (DCA), 2-amino-4- [3,4- (methylenedioxy) benzylamino] -6- (3-methoxyphenyl) pyrimidine, (hetero) arylpyrimidine of the formula where R is N- (3-1H-imidazol-1-yl) propane), N- (2-pyridin-4-yl) ethane ), N- (2-p iridin-3-yl) ethane), N- (3- (3,5-dimethyl-1H-pyrazol-1-yl) propyl), N- (2- (1H-indol-3-yl) ethane) or N - (S) -3- (1H-indol-3-yl) -2-propan-1-olamine, (hetero) arylpyrimidine of the formula wherein R 1 is CH-1H-imidazole, 4-pyridine, 3- (1H-indole), 3- (2-methyl-1H-indol-5-ol) or 4- (1H-imidazole), and R is 4- (pyridin-4-yl), 4- (pyridin-3-yl), 4- ( 3-nitrophenyl), 2- (benzo [b] thiophene) or 2- (naphthyl), (hetero) arylpyrimidine of the formula where R is H, ethyl, methylenecyclohexyl, 2-fluoro-3- (trifluorome |
| priorityDate | 2011-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.